Sanofi CFO on Growth Strategy, Valuation, Cost Cuts

The transcript discusses Sanofi's strategic focus under new leadership, emphasizing growth through both organic means and M&A activities. The company is leveraging its strong product pipeline, including Dupixent, to drive growth. Sanofi is also addressing its market position, aiming to align its stock valuation with peers. The company is confident in its competitive edge, particularly in allergy therapies, and is exploring opportunities in consumer healthcare. Financial targets include achieving a 30% operating margin by 2022, with a focus on execution and cost savings.

How does the leadership of Paul Hudson influence the company's strategy?

What are the two huge opportunities mentioned for the company's future growth?

What are the expectations for the operating margin by 2022?